Active, not recruitingNCT04919122
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Duke University
- Principal Investigator
- Daniel George, MDDuke University
- Enrollment
- 468 target
- Eligibility
- 19 years · All sexes
- Timeline
- 2022 – 2026
Study locations (14)
- State University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Ochsner Clinic Foundation d/b/a Ochsner Health, New Orleans, Louisiana, United States
- The Johns Hopkins University, Baltimore, Maryland, United States
- The Regents of the University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Duke University, Durham, North Carolina, United States
- The Ohio State University, Columbus, Ohio, United States
- Geisinger Clinic, Danville, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- The University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States
Collaborators
Duke Clinical Research Institute · Bristol-Myers Squibb · Exelixis · Merck Sharp & Dohme LLC · Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04919122 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →